LUNG Pulmonx Corporation
1.840USD+3.37%Mkt Cap: 77.72M $P/E: —1d ago
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobr…
Industry Peers
Medical DevicesKey Statistics
Company
Market Cap77.72M USD
Enterprise Value76.82M USD
Revenue (TTM)87.44M USD
Gross Profit67.14M USD
Net Income (TTM)-54.00M USD
Revenue/Share2.10 USD
Last Price1.840 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees296
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.89
PEG—
EV/EBITDA-1.69
EV/Revenue0.88
P/S0.86
P/B1.95
EPS (TTM)-1.15
EPS (Forward)-0.94
52W Range
1.13040% of range2.890
52W High2.890 USD
52W Low1.130 USD
Profitability
Gross Margin74.19%
Oper. Margin-39.80%
EBITDA Margin-52.02%
Profit Margin-59.67%
ROE-99.79%
ROA-41.77%
Growth
Revenue Growth-4.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.38M USD
CapEx (TTM)452.00K USD
FCF Margin-13.43%
FCF Yield-15.11%
Net Debt368.00K USD
Net Debt/EBITDA-0.01
Balance Sheet
Debt/Equity1.04
Current Ratio4.32
Quick Ratio3.36
Book Value/Sh0.91 USD
Cash/Share1.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.400 USD
Upside (mean)+84.8%
Target Range2.500 USD – 5.000 USD
2.500+84.8% to mean5.000
# Analysts5
Ownership
Shares Out.42.24M
Float37.61M
Insiders4.64%
Institutions62.81%
Short Interest
Short Ratio2.3d
Short % Float2.34%
Short % Out.1.97%
Shares Short847.84K
Short (prev mo.)1.07M
Technical
SMA 502.048 (-10.2%)
SMA 2001.679 (+9.6%)
Beta0.34
S&P 52W Chg16.45%
Avg Vol (30d)310.15K
Avg Vol (10d)215.08K
Technical Indicators
RSI (14)44.4
MACD-0.0450
MACD Signal-0.0211
MACD Hist.-0.0240
BB Upper2.100 USD
BB Middle1.933 USD
BB Lower1.766 USD
BB Width17.33%
ATR (14)0.1371 USD
Vol Ratio (20d)1.42x